Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 7/20 | 0.65 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.58 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.58 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.56 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.56 |
| ▸ | HTR3B | O95264 | 4/20 | 0.56 |
| ▸ | HTR3A | P46098 | 4/20 | 0.56 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.56 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.56 |
| ▸ | HTR1A | P08908 | 3/20 | 0.55 |
| ▸ | HTR7 | P34969 | 3/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.55 |
| ▸ | HTR1D | P28221 | 1/20 | 0.54 |
| ▸ | HTR1B | P28222 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 2/20 | 0.53 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL27692066 | 0.98 | ADRB1 (0.63) | ADRB1TGFBR1ACVR1ALKHTR3E | |
| Hydrochloric Acid SCHEMBL1638699 | 0.98 | ADRB1 (0.63) | ADRB1TGFBR1ACVR1ALKHTR3E | |
| SCHEMBL28116633 | 0.91 | ADRB1 (0.53) | ADRB1TGFBR1ACVR1ALKHTR3E | |
| SCHEMBL8182707 | 0.87 | ADRB1 (0.65) | ADRB1TGFBR1ACVR1ALKHTR3E | |
| SCHEMBL361649 | 0.85 | ADRB1 (0.61) | ADRB1TGFBR1ACVR1HTR3EHTR3B | |
| SCHEMBL13682933 | 0.83 | ALDH1A1 (0.58) | SUV39H2 | |
| SCHEMBL12625177 | 0.83 | ALDH1A1 (0.58) | SUV39H2 | |
| Hydrochloric Acid SCHEMBL7711565 | 0.83 | ADRB1 (0.59) | ADRB1TGFBR1ACVR1HTR3EHTR3B | |
| Hydrochloric Acid SCHEMBL2156292 | 0.83 | ADRB1 (0.59) | ADRB1TGFBR1ACVR1HTR3EHTR3B | |
| SCHEMBL2875460 | 0.83 | ADRB1 (0.59) | ADRB1TGFBR1ACVR1ALKHTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3468955-B1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2021-01-06 | — | — | EP | disclosed |
| EP-3468955-B1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2021-01-06 | — | — | EP | disclosed |
| US-10829478-B2 | 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis | GALAPAGOS NV (BE) | 2020-11-10 | — | — | US | disclosed |
| US-10829478-B2 | 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis | GALAPAGOS NV (BE) | 2020-11-10 | — | — | US | disclosed |
| US-20190315719-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-10-17 | — | — | US | disclosed |
| US-20190315719-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2019-10-17 | — | — | US | disclosed |
| US-20180250293-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX INC (US) | 2018-09-06 | — | — | US | disclosed |
| WO-2017211666-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | GALAPAGOS NV (BE) | 2017-12-14 | — | — | WO | disclosed |
| US-20160296517-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2016-10-13 | — | — | US | disclosed |
| US-20160296517-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CHEMOCENTRYX, INC. | 2016-10-13 | — | — | US | disclosed |
| CN-1155602-C | Thineopyranecarboxyamide derivatives | ��ޢ��ٻ�ѧ��ҩ��˾ | 2004-06-30 | — | — | CN | disclosed |
| US-20040082571-A1 | Substituted piperazines | CHEMOCENTRYX, INC. (US) | 2004-04-29 | — | — | US | disclosed |
| CN-1139579-C | Isoxazolecarboxamide derivatives | ��ޢ��ٻ�ѧ��ҩ��˾ | 2004-02-25 | — | — | CN | disclosed |
| WO-2003105853-A1 | 1-ARYL-4-SUBSTITUTED PIPERAZINES DERIVATIVES FOR USE AS CCR1 ANTAGONISTS FOR THE TREATMENT OF INFLAMMATION AND IMMUNE DISORDERS | CHEMOCENTRYX, INC. (US) | 2003-12-24 | — | — | WO | disclosed |
| CN-1128139-C | Novel piperazine derivative and process for producing the same | SAMJIN PHARM CO LTD (KR) | 2003-11-19 | — | — | CN | disclosed |
| CN-1118459-C | Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives as alpha1 adrenergic receptor antagonists | HOFFMANN LA ROCHE (CH) | 2003-08-20 | — | — | CN | disclosed |
| CN-1379767-A | Isoxazole carboxamide derivatives | RECORDATI CHEM PHARM (CH) | 2002-11-13 | — | — | CN | disclosed |
| CN-1365363-A | thineopyranecarboxyamide derivatives | RECORDATI CHEM PHARM (CH) | 2002-08-21 | — | — | CN | disclosed |
| CN-1149051-A | Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives as alpha1 adrenergic receptor antagonists | HOFFMANN LA ROCHE (CH) | 1997-05-07 | — | — | CN | disclosed |
| CN-1145620-A | New piperazine derivatives and its prepn. | SAMJIN PHARM CO LTD (KR) | 1997-03-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315719-A1 | 5-[3-[PIPERAZIN-1-YL]-3-OXO-PROPYL]-IMIDAZOLIDINE-2,4-DIONE DERIVATIVES AS ADAMTS 4 AND 5 INHIBITORS FOR TREATING E.G. OSTEOARTHRITIS | ADAMTS5, ADAMTS4, ADAMTS1 | ADRB1 3589/4885TGFBR1 436/4885ACVR1 331/4885 |
| US-20180250293-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | ADRB1 390/4885TGFBR1 791/4885ACVR1 1271/4885 |
| US-20160296517-A1 | AZAINDAZOLE COMPOUNDS AND METHODS OF USE | CCR1, CCR3, CCR4 | ADRB1 390/4885TGFBR1 791/4885ACVR1 1271/4885 |
| US-20040082571-A1 | Substituted piperazines | CCR1, CCR3, CCRL2 | ADRB1 294/4885TGFBR1 368/4885ACVR1 791/4885 |
| US-10829478-B2 | 5-[3-[piperazin-1-yl]-3-oxo-propyl]-imidazolidine-2,4-dione derivatives as ADAMTS 4 and 5 inhibitors for treating e.g. osteoarthritis | ADAMTS5, ADAMTS4, ADAMTS1 | ADRB1 3589/4885TGFBR1 436/4885ACVR1 331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.